866-997-4948(US-Canada Toll Free)

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 50 Pages

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Pipeline Review, H2 2017

Summary

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) pipeline Target constitutes close to 9 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Insulin Like Growth Factor I- Pipeline Review, H2 2017, outlays comprehensive information on the Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin. It plays a role in synapse maturation. It acts as a ligand for IGF1R. It binds to the alpha subunit of IGF1R, leading to the activation of the intrinsic tyrosine kinase activity which autophosphorylates tyrosine residues in the beta subunit thus initiates a cascade of down-stream signaling events leading to activation of the PI3K-AKT/PKB and the Ras-MAPK pathways. It binds to integrins ITGAV: ITGB3 and ITGA6:ITGB4. It also binds to integrins and subsequent ternary complex formation with integrins and IGFR1 are essential for IGF1 signaling. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 3, 1 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular and Musculoskeletal Disorders which include indications Metastatic Breast Cancer, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Breast Cancer, Cerebral Infarction (Brain Infarction), Hormone Sensitive Breast Cancer, Huntington Disease, Ischemic Cerebral Stroke, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Muscular Dystrophy, Neuroblastoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Parkinson's Disease, Prostate Cancer and Solid Tumor.

Furthermore, this report also reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)
- The report reviews Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Overview 6
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Companies Involved in Therapeutics Development 20
Boehringer Ingelheim GmbH 20
Genervon Biopharmaceuticals LLC 20
MedImmune LLC 21
Regulaxis SAS 21
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Drug Profiles 22
CIGB-845 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
dusigitumab - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
GM-6 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
M-610.27 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
M-630 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
M-7085 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Synthetic Peptides to Inhibit IGF1 for Oncology - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
xentuzumab - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Dormant Products 36
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Product Development Milestones 38
Featured News & Press Releases 38
Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published 38
Jan 10, 2017: Genervon Releases ALS, PD and AD Disease Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm 38
Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways 39
Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS 40
May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604 40
May 03, 2016: GM604 to Be Granted Orphan Drug Status in Europe 41
Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression 42
Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease 42
Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA 43
Jan 08, 2015: Genervon Announces ALS Compassionate Use Results 43
Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results 44
Jun 30, 2014: Genervon Announces Biomarker Data from GALS-001 Clinical Trial for ALS 46
Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS 47
Mar 03, 2014: FDA Grants Orphan Drug Designation for Genervons Breakthrough Multi-Target ALS Bio-Drug GM604 47
Jun 26, 2013: Genervon's GM604 Receives Fast Track Designation From FDA For Treatment Of Amyotrophic Lateral Sclerosis 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products under Investigation by Universities/Institutes, H2 2017 12
Products under Investigation by Universities/Institutes, H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Pipeline by Boehringer Ingelheim GmbH, H2 2017 20
Pipeline by Genervon Biopharmaceuticals LLC, H2 2017 20
Pipeline by MedImmune LLC, H2 2017 21
Pipeline by Regulaxis SAS, H2 2017 21
Dormant Products, H2 2017 36
Dormant Products, H2 2017 (Contd..1), H2 2017 37

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 16
Number of Products by Stage and Routes of Administration, H2 2017 16
Number of Products by Molecule Types, H2 2017 18
Number of Products by Stage and Molecule Types, H2 2017 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *